# MapLight Therapeutics Raises $372.5M Oversubscribed Series D for CNS Drug Pipeline

> financing · REPORTED · 2025-07-28

MapLight Therapeutics closed a $372.5 million oversubscribed Series D co-led by Forbion and Goldman Sachs Alternatives, with Sanofi, T. Rowe Price, and Novo Holdings among investors, to advance its oral M1/M4 muscarinic agonist ML-007C-MA through Phase 2 trials for schizophrenia and Alzheimer's disease psychosis. Described as one of the largest private biotech raises globally in 2025.

- Company: MapLight Therapeutics
- Sector: therapeutics
- Primary source: https://www.prnewswire.com/news-releases/maplight-therapeutics-announces-372-5-million-series-d-financing-302514844.html

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.